COVID-19 vaccine effectiveness
(Randomized evidence)
Methods
Analyses are updated every two weeks
On December 7, 2022, we published results of the systematic review "Efficacy and safety of COVID‐19 vaccines" which included 41 preprints and published trials of 12 different COVID-19 that were published before 5 November 2021.meta-COVID
Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:
Vaccine types
Vaccine efficacy and safety for vaccine vs placebo / no vaccine (forest plots)
Vaccine efficacy and safety for vaccine vs vaccine (forest plots)
Vaccine efficacy and safety against variants of concern (forest plots)
Vaccine efficacy, immunogenicity and safety of heterologous vs homologous vaccination (tables)
Vaccine efficacy, immunogenicity and safety of booster vs no booster (tables)
Vaccine efficacy, immunogenicity and safety of booster VS booster (tables)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04400838 ; ISRCTN University of Oxford/AstraZeneca Ramasamy MN, Lancet, 2020 Full text Commentary (20)32481-8/fulltext ; Commentary ; Commentary |
Non replicating viral vector |
Non replicating viral vector ChAdOx1 nCoV-19 vaccine - 2·2 × 10¹? vp x 2 doses on day 0/28 |
Non replicating viral vector ChAdOx1 nCoV-19 vaccine - 2·2 × 10¹? vp x 2 doses on day 0/28 |
RCTPhase 2/3 | Healthy adults in two centres in the UK | N=560 | N/A | |
|
NCT04568031 AstraZeneca+University of Oxford Asano M, Int J Infect Dis, 2021 Full text Commentary |
Non replicating viral vector |
ChAdOx1 |
Placebo |
RCTPhase 1-2 | Adults with or without mild, well-controlled co-morbidities seronegative and PCR negative to SARS-CoV-2 at 5 centres in Japan | N=256 |
Low Details |
|
|
NCT04907331; 2021-002171-19 AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma Bánki Z, EBioMedicine, 2022 HEVACC New Full text Commentary |
RNA based vaccine |
1 dose ChAdOx1/ 1 dose BNT162b2 |
ChAdOx1 |
RCTPhase 2 | Healthy adults with no history of COVID-19 in 3 centres in Austria. | N=234 |
Some concerns Details |
|
|
TCTR20211102003 Sinovac Research and Development Co., Ltd; Pfizer/BioNTech + Fosun Pharma; Moderna + National Institute of Allergy and Infectious Diseases (NIAID); AstraZeneca + University of Oxford Bruminhent J, Am J Transplant, 2022 Updated Full text Full text Commentary |
RNA based vaccine |
Boost BNT162b2 or mRNA-1273 |
Boost ChAdOx1 |
RCTPhase 3 | Adult kidney transplant recipients without a history of COVID-19 in a single centre in Thailand. | N=85 |
Some concerns Details |
|
|
NCT05054621 Medigen Vaccine Biologics+Dynavax+NIAID; AstraZeneca + University of Oxford Chen C, Nat Commun, 2022 New Full text Commentary Commentary |
Heterologous vaccination scheme |
1 dose ChAdOx1 / 1 dose MVC-COV1901 |
ChAdOx1 |
RCTPhase 2 | Healthy adults, HIV-negative and without severe disorders, who had received their initial ChAdOx1 dose at a single center in Taiwan. | N=100 |
Some concerns Details |
|
|
ISRCTN89951424 AstraZeneca+University of Oxford Clemens S, Nat. Commun., 2021 Full text Commentary Commentary |
Non replicating viral vector |
ChAdOx1 |
MenACWY |
RCTPhase 3 | Adults that were SARS-CoV-2 seronegative and with no history of COVID-19 in six centers in Brazil. | N=10416 |
Some concerns Details |
|
|
NCT05087368 Clover Biopharmaceuticals Inc./Dynavax ; AstraZeneca + University of Oxford Costa Clemens, Open Forum Infect. Dis., 2022 Full text Commentary Commentary Commentary Commentary |
Protein subunit |
ChAdOx1-S/booster 9 mcg SCB-2019 + alum ChAdOx1-S/booster 9 mcg SCB-2019 + CpG + alum ChAdOx1-S/booster 30 mcg SCB-2019 + CpG + alum |
ChadOx1/boostChadOx1 |
RCTPhase 2 | Adults including healthy or stable co-morbidities with no history of SARS-CoV-2 infection who had previously received 2 doses of ChAdOx1-S1-S vaccine 6 months (±4 weeks) before enrollment in 3 centers in Brazil | N=120 |
Some concerns Details |
|
|
RBR–9nn3scw AstraZeneca+University of Oxford/Sinovac/Janssen Pharmaceutical Companies/Pfizer/BioNTech+Fosun Pharma Costa Clemens SA, Lancet, 2022 Full text Commentary Commentary |
Non replicating viral vector |
CoronaVac/Boost BNT162b2 CoronaVac/Boost ChAdOx1 CoronaVac/Boost AD26.COV2-S |
CoronaVac/Boost CoronaVac |
RCTPhase 4 | Healthy adults with no history of confirmed covid-19 who had previously received 2 doses of CoronaVac at two centers in Brazil | N=1240 |
Some concerns Details |
|
|
NCT04400838 AstraZeneca+University of Oxford Emary K, Lancet, 2021 Full text Commentary |
Non replicating viral vector |
ChAdOx1 |
MenACWY |
RCTPhase 2-3 | Adults seronegative at baseline enrolled at 19 study sites in UK | N=10673 |
Some concerns Details |
|
|
INA-GO0HLGB AstraZeneca+University of Oxford;Pfizer/BioNTech + Fosun Pharma; Sinovac, Ltd Fadlyana E, Lancet Infect Dis, 2023 New Full text Commentary Commentary Commentary |
RNA based vaccine |
CoronaVac + boost BNT162b2 CoronaVac + boost BNT162b2 CoronaVac = booster BNT162b2 (half dose) Coronavac + boost ChAdOx1 (half dose) |
CoronaVac/Boost CoronaVac CoronaVac + boost BNT162b2 CoronaVac/Boost CoronaVac CoronaVac/Boost CoronaVac |
RCT* | Healthy adults without a history of laboratory confirmed COVID-19 within one month prior recruitment in 5 centres in Indonesia | N=960 |
Some concerns Details |
|
|
NCT04324606; ISRCTN15281137 AstraZeneca+University of Oxford Folegatti PM, Lancet, 2020 COV001 Full text Commentary ; Commentary (20)31611-1/fulltext |
Non replicating viral vector |
ChAdOx1 5x10^10 D1 |
MenACWY |
RCTPhase 1-2 | Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK | N=1067 |
Low Details |
|
|
NCT04526990 CanSino Biological Inc./Beijing Institute of Biotechnology Halperin SA, Lancet, 2021 Full text Commentary Commentary |
Non replicating viral vector |
Ad5-nCoV 5×10^10 vp |
Adjuvant |
RCTPhase 3 | Healthy adults with no history of laboratory-confirmed COVID-19 at 66 sites in Argentina, Chile, Mexico, Pakistan, and Russia | N=36982 |
Some concerns Details |
|
|
NCT04614948 Janssen Pharmaceutical Companies Hardt K, Lancet Infect Dis, 2022 b ENSEMBLE2 Full text Full text Commentary |
Non replicating viral vector |
Boost Ad26.COV2.S after prime vaccination with Ad26.COV2.S 5x10^10vp D0 |
Placebo |
RCTPhase 3 | Adults, healthy or with stable and well-controlled comorbidities, at 125 centers in Belgium, Brazil, Colombia, France, Germany, The Philippines, South Africa, Spain, UK, and USA | N=31835 |
Some concerns Details |
|
|
NCT04614948 Janssen Pharmaceutical Companies Hardt K, Lancet Infect Dis, 2022 a ENSEMBLE2 Full text Full text Commentary |
Non replicating viral vector |
Ad26.COV2.S 5x10^10vp D0 |
Placebo |
RCTPhase 3 | Adults, healthy or with stable and well-controlled comorbidities, at 125 centers in Belgium, Brazil, Colombia, France, Germany, The Philippines, South Africa, Spain, UK, and USA | N=31835 |
Some concerns Details |
|
|
NCT04952727 CanSino Biological Inc./Beijing Institute of Biotechnology ; Sinovac Research and Development Co., Ltd Jin P, medRxiv, 2022 a Full text Commentary Commentary |
Non replicating viral vector |
CoronaVac/Boost Ad5-vectored 5×10^10 vp |
CoronaVac/Boost CoronaVac |
RCTPhase 4 | Adults aged ≥60 years without severe or unstable comorbidities or confirmed history of COVID-19 or SARS-CoV-2 infection at a single center in China. | N=199 |
Some concerns Details |
|
|
NCT04444674 AstraZeneca + University of Oxford Koen A, medRxiv, 2022 COV005 Full text Full text Commentary |
Non replicating viral vector |
ChAdOx1 5x10^10 vp D0/28 |
Placebo D0/28 |
RCTPhase 1-2 | Healthy adults aged 18–65 years in 7 centres in South Africa | N=2130 |
Some concerns Details |
|
|
CTRI/2020/08/027170 Serum Institute of India/AstraZeneca+University of Oxford Kulkarni P, EClinicalMedicine, 2021 Full text Commentary |
Non replicating viral vector |
SII-ChAdOx1 nCoV-19 |
ChAdOx1 |
RCTPhase 2-3 | Adults (seronegative and seropositive) without a history of COVID and not immunocompromised at 14 centers in India | N=401 |
Low Details |
|
|
CTRI/2020/08/027170 Serum Institute of India/AstraZeneca+University of Oxford Kulkarni P, EClinicalMedicine, 2021 Full text (21)00499-5/fulltext#seccesectitle0022Commentary |
Non replicating viral vector |
SII-ChAdOx1 nCoV-19 |
Adjuvant |
RCTPhase 2-3 | Adults (seronegative and seropositive)without a history of COVID and not immunocompromised at 14 centers in India | N=1200 |
Low Details |
|
|
NCT04864561 Valneva Lazarus R, Lancet Infect Dis, 2022 Full text Commentary |
Inactivated virus |
VLA2001 |
ChAdOx1 |
RCTPhase 3 | Medically stable adults, 30 years and older, at 26 centers in the UK. | N=2975 |
Some concerns Details |
|
|
ISRCTN15638344; EudraCT 2020-005765-13 AstraZeneca+University of Oxford Li G, Lancet, 2022 a Full text Full text Commentary Commentary Commentary |
Non replicating viral vector |
ChAdOx1 ChAdOx1 D0/84 |
Placebo Placebo D0/84 |
RCTPhase 1-2 | Healthy adolescents aged 12-17 years with no history of COVID-19 at 4 centers in the UK | N=150 |
Some concerns Details |
|
|
NCT04892459 Sinovac Research and Development Co Ltd+CanSino Biological Inc / Beijing Institute of Biotechnology Li J, Nat. Med., 2022 Full text Commentary |
Non replicating viral vector |
1 dose CoronaVac / 1 dose Ad5-vectored |
2 doses CoronaVac |
RCTPhase 4 | Healthy adults with no previous clinical or virologic COVID-19 diagnosis or SARS-CoV-2 infection at one centre in China | N=100 |
Some concerns Details |
|
|
NCT04892459 Sinovac Research and Development Co Ltd + CanSino Biological Inc /Beijing Institute of Biotechnology Li J, Nat. Med., 2022 Full text Commentary |
Non replicating viral vector |
CoronaVac/boost Ad5-vectored 5×10^10 vp |
CoronaVac/boost |
RCTPhase 4 | Healthy adults with no previous clinical or virologic COVID-19 diagnosis or SARS-CoV-2 infection at one centre in China | N=200 |
Some concerns Details |
|
|
NCT04540419 CanSino Biological Inc./Beijing Institute of Biotechnology Lioznov D, medRxiv, 2022 Prometheus Full text Commentary Commentary |
Non replicating viral vector |
Ad5-nCoV 5x10^10vp D0 |
Placebo |
RCTphase 3 | Healthy adult volunteers without obesity with no current or previous SARS-CoV-2 infection in 6 centres in Russia. | N=500 |
Some concerns Details |
|
|
ISRCTN69254139, EudraCT: 2020-005085-33 AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma Liu X, Lancet, 2022 Com-COV Full text Full text Commentary Commentary |
RNA based vaccine |
1 dose ChAdOx1/ 1 dose BNT162b2 1 dose BNT162b2 /1 dose ChAdOx1 |
2 doses ChAdOx1 2 doses BNT162b2 |
RCTPhase 2 | Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK | N=463 |
Some concerns Details |
|
|
NCT04530396 Gamaleya Research Institute (Sputnik V) Logunov D, Lancet, 2021 RESIST Full text Commentary ; Commentary ; Commentary |
Non replicating viral vector |
Gam-COVID-Vac rAd26-S |
Placebo D0/21 |
RCTPhase 3 | SARS-CoV-2- and HIV infection-free adult volunteers at 25 centers in Russia | N=21977 |
Some concerns Details |
|
|
NCT04962906; NCT05027672 Gamaleya Research Institute, AstraZeneca+University of Oxford;Moderna;Sinopharm Macchia A, Lancet Reg Health Am, 2022 Full text Commentary |
Non replicating viral vector |
Gam-COVID-Vac rAd26-S |
Gam-COVID-Vac rAd26-S/BBIBP-CorV |
RCTPhase 2 | Adults who had received the first dose (rAd26) of the Sputnik V vaccine at least 30 days earlier and no history of SARS-CoV-2 at a single centre in Argentina | N=540 |
Some concerns Details |
|
|
NCT04444674, PACTR202006922165132 AstraZeneca+University of Oxford Madhi S, Lancet, 2021 Full text Commentary |
Non replicating viral vector |
BNT162b1 30 mcg |
Placebo |
RCTPhase 1-2 | Adults living with HIV in 7 centers in South Africa | N=104 |
Low Details |
|
|
ISRCTN73765130 AstraZeneca + University of Oxford; Janssen Pharmaceutical; Novovax; Moderna + NIAID; Pfizer BioNTech + Fosun Pharma; CureVac AG; Valneva, NIHR, UK Munro A , Lancet, 2021 a COV-BOOST Full text Commentary |
Non replicating viral vector |
ChadOx1/boost ChadOx1 ChadOx1/boost Novavax ChadOx1/boost Novavax half dose |
ChadOx1/Placebo |
RCTPhase 2 | Adults aged ≥30 years in good physical health at 18 centers in the UK. | N=443 |
Some concerns Details |
|
|
TCTR20210722003 AstraZeneca+University of Oxford Nanthapisal S, Vaccine, 2022 Full text Commentary Commentary |
Non replicating viral vector |
CoronaVac/Boost ChAdOx1 |
CoronaVac Boosted by low dose ChAdOx1 |
RCTPhase 2 | Healthy adult volunteers with no history or current infection with SARS-CoV-2 who had completed two doses of CoronaVac at 2 centres in Thailand. | N=422 |
Some concerns Details |
|
|
EudraCT021-002927-39 Pfizer/BioNTech+Fosun Pharma/Moderna/Janssen Pharmaceutical Companies Reindl-Schwaighofer R, JAMA, 2021 Full text Full text Commentary Commentary |
RNA based vaccine |
mRNA-1273 or BNT162b2/homologous booster |
mRNAorBNT/Ad26COVS1 booster |
RCTPhase 2 | Adult kidney transplant recipients with no history of COVID-19 infection and without an antibody response 4 weeks after a 2-dose mRNA vaccine schedule at a single center in Austria. | N=201 |
Some concerns Details |
|
|
CTRI/2021/08/035648 AstraZeneca + University of Oxford; Bharat Biotech Rose W, SSRN, 2022 Full text Commentary Commentary |
Inactivated virus |
ChadOx1/boostBBV152 BBV152/boostChadOx1 |
ChadOx1/boostChadOx1 BBV152 Booster |
RCTPhase 4 | Adults that were SARS-CoV-2 infection-free in a single centre in India | N=405 |
Low Details |
|
|
NCT04927936 Janssen Pharmaceutical;Moderna ;Pfizer/BionTech+Fosun Pharma Sablerolles R, N Engl J Med, 2022 Full text Full text Commentary Commentary |
Non replicating viral vector |
Ad26.COV2.S/m-RNA-1273 Ad26.COV2.S/Ad26.COV2.S Ad26.COV2.S/BNT162b2 |
Ad26.COV2.S/No boost |
RCTPhase 3 | Healthcare workers aged 18-65 years, without severe comorbidities, and no known history of SARS-CoV-2 infection who received a single Ad26.COV2.S primary vaccination at 4 centers in the Netherlands. | N=461 |
Some concerns Details |
|
|
NCT04436276 Janssen Pharmaceutical Companies Sadoff J, N Engl J Med, 2021 a ENSEMBLE Full text Commentary |
Non replicating viral vector |
Ad26.COV2.S, 5x10^10vp |
0.9% saline placebo |
RCTPhase 1-2 | Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US | N=810 |
Low Details |
|
|
NCT04505722 Janssen Pharmaceutical Companies Sadoff J, N Engl J Med, 2022 b ENSEMBLE Full text Commentary |
Non replicating viral vector |
Ad26.COV2.S 5x10^10vp |
Placebo |
RCTPhase 3 | Adults >18 years of age at 213 centers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and USA | N=44325 |
Some concerns Details |
|
|
NCT04516746 AstraZeneca+University of Oxford Sobieszczyk M, J Clin Invest, 2022 Full text Commentary Commentary |
Non replicating viral vector |
ChAdOx1 |
Placebo |
RCTPhase 3 | Adults (22% over 65 years) at high risk for exposure to SARS-CoV-2 and populations at increased risk for Covid-19 complications at 88 sites in USA, Chile, and Peru | N=32450 |
Some concerns Details |
|
|
NCT04436276 Janssen Pharmaceutical Companies Stephenson K, JAMA, 2021 Full text Commentary Commentary |
Non replicating viral vector |
Ad26.COV2.S |
Placebo |
RCTPhase 1 | Healthy adults aged 18-55 years that were SARS-CoV-2 infection-free in a single centre in USA. | N=10 |
Low Details |
|
|
ISRCTN27841311; EudraCT 2021-001275-16 AstraZeneca + University of Oxford / Novavax / Moderna + NIAID Stuart A, Lancet, 2021 a Com-COV2 Full text Commentary Commentary |
Protein subunit |
1 dose ChAdOx1 followed by 1 dose NVX-CoV2373 1 dose ChAdOx1 followed by 1 dose mRNA-1273 |
2 doses ChAdOx1 |
RCTPhase 2 | Healthy adults over 50 years previously vaccinated with one dose of ChAdOx1 nCoV-19 in 9 centres in the UK | N=540 |
Some concerns Details |
|
|
TCTR20210731003 AstraZenec+University of Oxford /Sinovac Tawinprai K, Vaccine, 2022 Full text Commentary |
Non replicating viral vector |
Coronavac + boost ID 2/5 ChAdOx1 Coronavac + boost ID 1/5 ChAdOx1 |
Coronavac + boost ChAdOx1 |
RCTPhase 2 | Adults who had received a 2-dose primary Coronavac schedule at least 2 months previously at a single center in Thailand. | N=207 |
Details |
|
|
CTRI/2021/08/036074 Biological E;AstraZeneca+University of Oxford Thuluva , medRxiv, 2022 b Full text Commentary Commentary |
Protein subunit |
2 IM doses of 25 mcg BECOV2 |
ChAdOx1 |
RCTPhase 3 | Healthy adults without a history of Covid-19 vaccination or SARS-CoV-2 infection at 20 centers in India. | N=2140 |
Some concerns Details |
|
|
NCT05011526 Medigen; AstraZeneca + University of Oxford Torales J, Vaccine, 2022 Full text Full text Commentary Commentary |
Protein subunit |
MVC-COV1901 15 mcg D0/28 |
ChAdOx1 |
RCTPhase 3 | Healthy adults or adults with pre-existing medical conditions who are in stable condition and with no known SARS-CoV-2 infection in the 3 months prior at 2 centers in Paraguay. | N=1030 |
Some concerns Details |
|
|
ISRCTN89951424 AstraZeneca+University of Oxford Voysey M, Lancet, 2020 COV003 Full text Commentary |
Non replicating viral vector |
ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (3.5 - 6.5 x 10^10vp) |
Meningococcal group A, C, W-135, and Y conjugate vaccine Day 0, saline 0.5mL (0.9% NaCl) Day 28 |
RCTPhase 3 | Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil | N=10002 |
Some concerns Details |
|
|
NCT04400838 AstraZeneca+University of Oxford Voysey M, Lancet, 2020 COV002 Full text Commentary |
Non replicating viral vector |
ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (2·2 × 10¹? vp) /0.5mL (3.5 - 6.5 x 10¹?vp) ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (3.5 - 6.5 x 10¹?vp) |
Meningococcal group A, C, W-135, and Y conjugate vaccine 0.5mL, 2 x doses, Days 0/28 |
RCTPhase 2/3 | Healthy adults in 18 centres in the UK | N=10673 |
Some concerns Details |
|
|
ISRCTN89951424 (COV0 AstraZeneca+University of Oxford Voysey M, Lancet, 2020 COV002/3 Full text Commentary |
Non replicating viral vector |
ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (2·2 × 10¹? vp or 3.5 - 6.5 x 10¹?vp) /0.5mL (3.5 - 6.5 x 10¹?vp) |
ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (2·2 × 10¹? vp or 3.5 - 6.5 x 10¹?vp) /0.5mL (3.5 - 6.5 x 10¹?vp) |
RCTPhase 2/3 | Healthy adults from two studies in multiple centres in Brazil and the UK | N=20675 | N/A | |
|
NCT04324606;ISRCTN89951424;NCT04400838;NCT04444674 AstraZeneca+University of Oxford Voysey M, Lancet, 2021 COV001/COV002/COV003/COV005 Full text Commentary ; Commentary ; Commentary |
Non replicating viral vector |
ChAdOx1 nCoV-19 vaccine, 2 doses, low/standard or standard/standard |
MenACWY vaccine/ placebo |
RCTPhase 1/2/3 | Adults seronegative at baseline from four studies in multiple centres in Brazil, South Africa, and the UK | N=24422 |
Some concerns Details |
|
|
NCT04552366 Beijing Institute of Biotechnology, Beijing, China, and CanSino Biologics Wu S, Lancet, 2021 Full text Commentary |
Non replicating viral vector |
Ad5-nCoV 2x10^10 vp mu D0/28 Ad5-nCoV 2x10^10 vp mu D0/28 Ad5-nCoV 2x10^10 vp mu D0/28 Ad5-nCoV 2x10^10 vp mu D0/28 |
Ad5-nCoV 1x10^10 vp mu D0/28 Ad5-nCoV 5x10^10 vp im D0/ Ad5-nCoV 2x10^10 vp mu D28 Ad5-nCoV 5x10^10 vp im D0 Ad5-nCoV 10x10^10 vp im D0 |
RCTPhase 1 | Adults who were HIV-negative and seronegative for SARS-CoV-2 at a single center in China | N=130 |
Some concerns Details |
|
|
NCT04341389 CanSino Biological Inc./Beijing Institute of Biotechnology Zhu F, Lancet, 2020 Full text Commentary Commentary |
Non replicating viral vector |
Ad5-nCoV 5×10^10 vp D0 |
Adjuvant |
RCTPhase 2 | Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China. | N=508 |
Low Details |
|
|
NCT04566770 CanSino Biological Inc./Beijing Institute of Biotechnology Zhu F , Clin. Infect. Dis., 2021 b Full text Commentary Commentary |
Non replicating viral vector |
Ad5-nCoV 3x10¹⁰ vp |
Ad5-nCoV 3x10¹⁰ vp |
RCTPhase 2b | Healthy children and adolescents aged 6-17 years that were HIV-negative and SARS-CoV-2 infection-free in a single centre in China. | N=150 |
Low Details |
|
|
NCT04566770 CanSino Biological Inc./Beijing Institute of Biotechnology Zhu F, Research Square, 2021 d Full text Commentary Commentary |
Non replicating viral vector |
Ad5-vectored 5x10^10 vp |
Placebo |
RCTPhase 2b | Healthy adults aged 18-55 years, HIV-negative and SARS-CoV-2 infection-free in a single centre in China. | N=30 |
Low Details |
|
|
NCT04566770 CanSino Biological Inc./Beijing Institute of Biotechnology Zhu F, Clin Infect Dis, 2021 a Full text Commentary Commentary |
Non replicating viral vector |
Ad5-vectored 5×10^10 vp Ad5-vectored 10×10^10 vp |
Placebo |
RCTPhase 2b | Healthy volunteers aged 56 years and above that were HIV-negative and SARS-CoV-2 infection-free in a single centre in China. | N=250 |
Low Details |
|